依普利酮医保给报销吗？

Product name: Planep. Eplerenone is a new, highly selective aldosterone receptor blocker that can be used for the treatment of heart failure, hypertension, and coronary heart disease. Eplerenone was developed by Pfizer and first launched in the United States in 2002. Eplerenone is not currently on the market in my country, so it cannot be reimbursed by medical insurance.

Eplerenone can be used alone or in combination with other antihypertensive drugs to treat hypertension. The recommended dose for adults is the initial dose: 50 mg orally once daily. Maintenance dose: 50 mg orally, 1-2 times daily. Maximum dose: 100 mg/day. Obvious antihypertensive effects appear within four weeks of taking the drug. Patients whose blood pressure responds inadequately to the initial dose may be increased to 50 mg twice daily.

Subgroup analysis of the EPHESUS study also showed that the effect of eplerenone on reducing overall mortality was more obvious in patients with hypertension. A comparative study on the efficacy and tolerability of 499 patients with grade 1 or 2 hypertension who were randomized to receive enalapril or eplerenone showed that at 6 months, enalapril was as effective as eplerenone in reducing systolic blood pressure (14.5 mmHg for eplerenone; 12.7 mmHg for enalapril: P=0.199) and diastolic blood pressure (11.2 mmHg for eplerenone; 11.3 mm for enalapril). Hg; P=0.910). After 12 months, the two groups were also similar (eplerenone -16.5/-13.3mmHg; enalapril -14.8/-14.1mmHg, P values ​​0.251 and 0.331 respectively). Dropout due to adverse events (7.9% for eplerenone and 9.3% for enalapril at 6 months) and treatment failure rates were also equal (23.3% for eplerenone and 22.8% for enalapril at 6 months). About 2/3 of the patients in each group achieved normal blood pressure at 6 months with the above single treatment. In the eplerenone group, the reduction in blood pressure was independent of renin levels, unlike enalapril. Both groups can reduce proteinuria above normal levels, but the treatment effect is more obvious in the treatment group (-61.5% vs -25.7%; P=0.01).